Find clinical trials for Melanoma in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Melanoma trials near Paris, Île-de-France, FRA:
of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations....
Phase 1, Phase 2
Paris, France and 10 other locations
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
Paris, France and 22 other locations
ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph ...
Phase 2
Paris, France and 9 other locations
therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...
Phase 2, Phase 3
Paris, France and 70 other locations
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Boulogne Billancourt cedex, Hauts-de-Seine, France and 105 other locations
the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...
Phase 3
Paris Cedex 10, Paris, France and 154 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:is advanced or metastatic (spread to other parts of the bo...
Phase 3
Villejuif, France and 227 other locations
the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma...
Phase 2
Paris, France and 18 other locations
of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...
Phase 1, Phase 2
Paris, France and 24 other locations
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...
Phase 2
Villejuif Cedex, Ile-de-france, France and 56 other locations
Clinical trials
Research sites
Resources
Legal